Eftychia Lekka, Ph.D. and Vassilis Virvilis, Ph.D Biovista Efforts to standardize important concepts and relationships using established Terminologies in the AOP Knowledge Base at NIH’s Predictive Toxicology Branch DNTP Seminar on Friday June 24 2022. The presentation will summarize a systematic approach on reviewing and categorizing user-entered data issues in the Adverse Outcome Pathway (AOP) … Read More
Biovista is pleased to announce the appointment of a Business Development Agent in Japan. Based in Tokyo, our BD Agent will serve Biovista customers and collaborators throughout Japan. Our agent will focus on Biovista’s new therapy development services and will serve as the main contact point for our Japanese customers. Additionally, our Agent will support … Read More
Biovista is pleased to announce the signature of a grant agreement within the remit of the EU’s Innovative Medicines Initiative (IMI). Starting in March 2019, the 3.5 year “NeuroDeRisk” project aims to advance the industry’s ability to tackle three of the most challenging adverse effects: seizures, psychological/psychiatric changes, and peripheral neuropathies. Together with EFPIA members … Read More
Biovista is pleased to announce that its patent application for the use of tetracyclic pyrazinoindoles has issued in the EU. This new patent (European patent No.: 2375900) has title “METHODS FOR TREATING MULTIPLE SCLEROSIS USING TETRACYCLIC PYRZINOINDOLES” was issued on March 2, 2016.
Current therapeutic strategies for myalgic encephalomyelitis/chronic fatigue syndrome: results of an online survey A new paper co-authored by Biovista and the Solve ME/CFS Initiative has just been published. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex, poorly understood disorder that causes only a small number of the approximately 2.5 million Americans to receive proper diagnosis. … Read More